These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30154359)

  • 41. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
    Lin CW; Dutta S; Zhao W; Asatryan A; Campbell A; Liu W
    Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):81-90. PubMed ID: 28688001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].
    Sánchez Suárez MM; Martín Roldán A; Cantudo Cuenca MR
    Rev Esp Quimioter; 2024 Jun; 37(3):283-284. PubMed ID: 38638059
    [No Abstract]   [Full Text] [Related]  

  • 44. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
    Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
    Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
    J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
    Umemura M; Suda G; Tsukamoto S; Ebata K; Takahash S; Sasaki T; Nakajima S; Hirata K; Ozasa M; Takano M; Katagiri M; Sakamoto N
    BMC Infect Dis; 2021 Apr; 21(1):389. PubMed ID: 33906643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
    Toyoda H; Chayama K; Suzuki F; Sato K; Atarashi T; Watanabe T; Atsukawa M; Naganuma A; Notsumata K; Osaki Y; Nakamuta M; Takaguchi K; Saito S; Kato K; Pugatch D; Burroughs M; Redman R; Alves K; Pilot-Matias TJ; Oberoi RK; Fu B; Kumada H
    Hepatology; 2018 Feb; 67(2):505-513. PubMed ID: 28865152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
    Lampertico P; Mauss S; Persico M; Barclay ST; Marx S; Lohmann K; Bondin M; Zhang Z; Marra F; Belperio PS; Wedemeyer H; Flamm S
    Adv Ther; 2020 Sep; 37(9):4033-4042. PubMed ID: 32754824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
    Foster GR; Asselah T; Kopecky-Bromberg S; Lei Y; Asatryan A; Trinh R; Zadeikis N; Mensa FJ
    PLoS One; 2019; 14(1):e0208506. PubMed ID: 30601818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.
    Ohya K; Imamura M; Osawa M; Teraoka Y; Morio K; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Hiramatsu A; Tsuge M; Aikata H; Hayes CN; Chayama K
    Clin J Gastroenterol; 2020 Apr; 13(2):267-270. PubMed ID: 31463795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
    J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
    Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
    Madsen LW; Christensen PB; Fahnøe U; Pedersen MS; Bukh J; Øvrehus A
    Liver Int; 2021 Nov; 41(11):2601-2610. PubMed ID: 34154034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
    Peribañez-Gonzalez M; Cheinquer H; Rodrigues L; Lima MP; Álvares-da-Silva MR; Madruga J; Parise ER; Pessoa MG; Furtado J; Villanova M; Ferreira A; Mazzoleni F; Nascimento E; Silva GF; Fredrick L; Krishnan P; Burroughs M; Reuter T
    Ann Hepatol; 2021; 20():100257. PubMed ID: 32949786
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
    Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
    Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
    Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ
    Int J Drug Policy; 2019 Apr; 66():73-79. PubMed ID: 30735896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
    Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
    J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
    Back D; Belperio P; Bondin M; Negro F; Talal AH; Park C; Zhang Z; Pinsky B; Crown E; Mensa FJ; Marra F
    J Viral Hepat; 2019 Aug; 26(8):951-960. PubMed ID: 30977945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.